Navigation Links
Scientists discover new drug candidates for cystic fibrosis and other diseases
Date:11/1/2011

Bethesda, MDA new discovery by Californian scientists may lead to a pharmaceutical breakthrough for a wide range of illnesses that involve the hydration of cells that line the inner surfaces of our body's organs and tissues. In a new report appearing in the FASEB Journal (http://www.fasebj.org), the researchers describe how they used high-throughput screening to identify small-molecule drug candidates which help cells bypass defective channels that normally move salt and water through cell membranes. These drug candidates work by activating an alternative chloride channel called "TMEM16A" that might be effective in treating conditions such as cystic fibrosis, dry eye and dry mouth diseases and slow-transit constipation.

"Further pre-clinical development of the chloride channel activators identified in our study may lead to new drug therapies for cystic fibrosis, dry eye and mouth syndromes, and certain types of constipation," said Alan S. Verkman, M.D., Ph.D., study author from the Department of Medicine at the University of California, San Francisco.

Verkman and colleagues discovered these compounds by using high-throughput screening, in which more than 100,000 drug-like compounds were tested for their ability to activate the TMEM16A channel. Active compounds coming from the screen were further improved and tested in cell and mouse models. These compounds were found to help facilitate salt and water movement, making them promising drug candidates.

"Scientists have known for decades that cells have more than one way to move salt and water. Indeed, over the years many useful drugs have been developed that influence these movements in the heart and kidneys," said Gerald Weissmann, M.D., Editor-in-Chief of the FASEB Journal. "This discovery is important not only because it identifies a new channel present all over the body, but finds a promising agent to activate it. As further drug candidates are devised to target TMEM16A, this work may lead to clinical advances of major significance."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. Gladstone scientists identify protein form linked to Huntingtons disease
2. Scientists chart gene expression in the brain across lifespan
3. Scientists measure dream content for the first time
4. A*STAR scientists first to identify stem cell key to lung regeneration
5. UK scientists come together to help feed the 7 billion
6. Geoscientists find key to why some patients get infections from cardiac implants
7. Scientists determine family tree for most-endangered bird family in the world
8. Philadelphia scientists to be honored with the John Scott Award
9. 46 outstanding life scientists elected to EMBO membership
10. Scientists report major advance in human antibody therapy against deadly Hendra virus
11. Magnifying research: Scientists team together to upgrade supercomputer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... , Jan. 20, 2016 A market ... to directly benefit from the explosion in genomics knowledge. ... Howe Sound Research. A range of dynamic trends are ... - personalized medicine - pharmacogenomics - pathogen evolution ... with large markets - greater understanding of the role ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the ... nearly 10,000 retail locations, web and mobile, today ... $40 million from existing investors. ... be devoted to further innovate higi,s health platform ... and web portal – including expanding services and ...
Breaking Biology News(10 mins):
(Date:2/9/2016)... -- Three-Year Initiative Supports Next Generation of Medical ... Life-Changing Camp Experiences ... the lives of children born with rare diseases, as well as ... is announcing a new initiative designed to positively affect the lives ... of rare disease care. --> To mark the company,s ...
(Date:2/9/2016)... 2016 DelveInsight,s, "Protein-Tyrosine ... provides in depth insights on the pipeline ... Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. The DelveInsight,s ... stages of development including Discovery, Pre-clinical, IND, ... Preregistration. Report covers the product clinical trials ...
(Date:2/8/2016)... , Feb. 8, 2016 Should antibiotic bone ... cement products to prevent infection after standard total hip ... experts at ECRI Institute have been fielding a lot ... Fighting Your Bottom Line?" --> ... Line?" --> While there isn,t ...
(Date:2/8/2016)... , February 8, 2016 ... Oncology Private Limited, an innovation-driven oncology company developing ... and less toxic, today announced that chairman emeritus ... has invested in the company as part of ... round, joining existing investors Navam Capital and Aarin ...
Breaking Biology Technology: